These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20859246)

  • 21. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
    Tsai SJ; Hong CJ; Liou YJ; Chen TJ; Chen ML; Hou SJ; Yen FC; Yu YW
    Psychiatry Res; 2009 Sep; 169(2):113-7. PubMed ID: 19700204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid autoimmunity and treatment response to escitalopram in major depression.
    Eller T; Metsküla K; Talja I; Maron E; Uibo R; Vasar V
    Nord J Psychiatry; 2010 Aug; 64(4):253-7. PubMed ID: 20088751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
    Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
    Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P; Lönn SL; Overø KF
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.
    Yu AP; Xie J; Bensimon A; Parikh K; Wu EQ; Ben-Hamadi R; Blum S; Haim Erder M
    J Med Econ; 2010; 13(4):599-609. PubMed ID: 20879834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
    Amsterdam JD; Shults J; Rutherford N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):100-6. PubMed ID: 17804135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Placebo response and antidepressant response.
    Alexopoulos GS; Kanellopoulos D; Murphy C; Gunning-Dixon F; Katz R; Heo M
    Am J Geriatr Psychiatry; 2007 Feb; 15(2):149-58. PubMed ID: 17272735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression.
    Linka T; Müller BW; Bender S; Sartory G
    Neurosci Lett; 2004 Sep; 367(3):375-8. PubMed ID: 15337269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
    Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
    Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM
    Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram plasma levels and antidepressant response.
    Florio V; Porcelli S; Saria A; Serretti A; Conca A
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):940-944. PubMed ID: 28648553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood microRNA changes in depressed patients during antidepressant treatment.
    Bocchio-Chiavetto L; Maffioletti E; Bettinsoli P; Giovannini C; Bignotti S; Tardito D; Corrada D; Milanesi L; Gennarelli M
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):602-11. PubMed ID: 22925464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
    Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.
    Kuo HW; Liu SC; Tsou HH; Liu SW; Lin KM; Lu SC; Hsiao MC; Hsiao CF; Liu CY; Chen CH; Lu ML; Shen WW; Tang HS; Liu SI; Chang LH; Wu HY; Chang YS; Yeh TK; Chen ACh; Liu YL
    Pharmacogenomics; 2013 Jul; 14(10):1191-201. PubMed ID: 23859573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.